Evidence map›Paper›PMID 16500892›Full record

ArticleNucleic acids research2006

Kruppel-like factor 5 is an important mediator for lipopolysaccharide-induced proinflammatory response in intestinal epithelial cells.

Sengthong Chanchevalap, Mandayam O Nandan, Beth B McConnell, Laetitia Charrier, Didier Merlin, Jonathan P Katz, Vincent W Yang

Open access · goldAbstract read
In one paragraph

Article in Nucleic acids research, 2006. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 53 papers.

0numbers the graph read from it
0cells of the map it votes in
53citing papers in PubMed
3.3field-weighted citation impact, top 8% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

53 citing papers in PubMed, 95 citations in OpenAlex.

  1. Article
  2. Cells · 2025
    Review
  3. Article
  4. Review
  5. Article
  6. Review
  7. Article
  8. Article
  9. Article
  10. Review
  11. Roles of Krüppel-like factor 5 in kidney disease.Journal of cellular and molecular medicine · 2021
    Review
  12. Article
  13. Article
  14. Article
  15. The roles of TNFAIP2 in cancers and infectious diseases.Journal of cellular and molecular medicine · 2018
    Review
  16. Article
  17. Article
  18. Article
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 1 institution in 1 country.

Sengthong ChanchevalapDivision of Digestive Diseases, Department of Medicine, Emory University School of Medicine Atlanta, GA, USA.
Mandayam O Nandan
Beth B McConnell
Laetitia Charrier
Didier Merlin
Jonathan P Katz
Vincent W Yang
Emory University · US

Funding

REGULATION OF INTESTINAL EPITHELIAL CELL PROLIFERATIONR01DK052230 · NIDDK · STATE UNIVERSITY NEW YORK STONY BROOK · PI Vincent W Yang · 1997 to 2026
$8.7M
MECHANISMS OF INTESTINAL TUMORIGENESISR01CA084197 · NCI · STATE UNIVERSITY NEW YORK STONY BROOK · PI YANG, VINCENT W · 2000 to 2020
$7.5M
Emory Epithelial Pathobiology Research Development CenterR24DK064399 · NIDDK · EMORY UNIVERSITY · PI PARKOS, CHARLES A · 2003 to 2012
$5.3M
NCI NIH HHS CA84197NCI NIH HHS R01 CA084197NIDDK NIH HHS DK52230NIDDK NIH HHS DK64399NIDDK NIH HHS R01 DK052230NIDDK NIH HHS R01 DK52230NIDDK NIH HHS R24 DK064399
6 · The paper itself

Abstract

Lipopolysaccharide (LPS) is a bacterially-derived endotoxin that elicits a strong proinflammatory response in intestinal epithelial cells. It is well established that LPS activates this response through NF-kappaB. In addition, LPS signals through the mitogen-activated protein kinase (MAPK) pathway. We previously demonstrated that the Krüppel-like factor 5 [KLF5; also known as intestine-enriched Krüppel-like factor (IKLF)] is activated by the MAPK. In the current study, we examined whether KLF5 mediates the signaling cascade elicited by LPS. Treatment of the intestinal epithelial cell line, IEC6, with LPS resulted in a dose- and time-dependent increase in KLF5 messenger RNA (mRNA) and protein levels. Concurrently, mRNA levels of the p50 and p65 subunits of NF-kappaB were increased by LPS treatment. Pretreatment with the MAPK inhibitor, U0126, or the LPS antagonist, polymyxin B, resulted in an attenuation of KLF5, p50 and p65 NF-kappaB subunit mRNA levels from LPS treatment. Importantly, suppression of KLF5 by small interfering RNA (siRNA) resulted in a reduction in p50 and p65 subunit mRNA levels and NF-kappaB DNA binding activity in response to LPS. LPS treatment also led to an increase in secretion of TNF-alpha and IL-6 from IEC6, both of which were reduced by siRNA inhibition of KLF5. In addition, intercellular adhesion molecule-1 (ICAM-1) levels were increased in LPS-treated IEC6 cells and this increase was associated with increased adhesion of Jurkat lymphocytes to IEC6. The induction of ICAM-1 expression and T cell adhesion to IEC6 by LPS were both abrogated by siRNA inhibition of KLF5. These results indicate that KLF5 is an important mediator for the proinflammatory response elicited by LPS in intestinal epithelial cells.

Indexed as

AnimalsCell AdhesionCell LineEpithelial CellsHumansInflammation MediatorsIntercellular Adhesion Molecule-1Interleukin-6Intestinal MucosaJurkat CellsKruppel-Like Transcription FactorsLipopolysaccharidesMiceNF-kappa BRNA InterferenceRNA, MessengerInflammation MediatorsIntercellular Adhesion Molecule-1Interleukin-6Klf5 protein, mouseKruppel-Like Transcription FactorsLipopolysaccharidesNF-kappa BRNA, MessengerTumor Necrosis Factor-alpha

Identifiers

PMID16500892
PMCPMC1383625
OpenAlexW2131906304

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.